Effect of V(IV)O(dipic-Cl)(H(2)O)(2) on Lipid Metabolism Disorders in the Liver of STZ-Induced Diabetic Rats

Vanadium complexes are potent antidiabetic agents for therapeutical treatment of diabetes. In the present study, we investigated the hypolipidemic effect of V(IV)O(dipic-Cl)(H(2)O)(2) (V(4)dipic-Cl) in liver of streptozotocin- (STZ-)-induced diabetic rats. We found that diabetic animals exhibited he...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fang, Xie, Mingxia, Chen, Deliang, Li, Jian, Ding, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647472/
https://www.ncbi.nlm.nih.gov/pubmed/23691525
http://dx.doi.org/10.1155/2013/956737
Descripción
Sumario:Vanadium complexes are potent antidiabetic agents for therapeutical treatment of diabetes. In the present study, we investigated the hypolipidemic effect of V(IV)O(dipic-Cl)(H(2)O)(2) (V(4)dipic-Cl) in liver of streptozotocin- (STZ-)-induced diabetic rats. We found that diabetic animals exhibited hepatic inflammatory infiltration and impaired liver function along with triglyceride (TG) accumulation in the liver. V(4)dipic-Cl treatment not only ameliorated liver pathological state but also reduced hepatic TG level. Moreover, the upregulation of fatty acid translocase (FAT/CD36) mRNA (4.0-fold) and protein (8.2-fold) levels in the liver of diabetic rats were significantly reversed after V(4)dipic-Cl treatment. However, no significant effects of V(4)dipic-Cl on the mRNA expression of fatty acid metabolism-related fatty acid bounding protein 1 (FABP1) and fatty acid transporter 5 (FATP5) were observed. These results suggest that the modification of lipid metabolism-related FAT/CD36 in the liver of diabetic rats is likely involved in the hypolipidemic effects of V(4)dipic-Cl.

Ejemplares similares